tiprankstipranks
Advertisement
Advertisement

OKYO Stock Latest News

OKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver
Company AnnouncementsOKYO Pharma to Showcase Urcosimod NCP Data at May Ophthalmology Meetings in Denver
10d ago
6K
OKYO
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting
PremiumCompany Announcements
OKYO Pharma to Showcase Urcosimod Data and Convene Key Advisory Board at 2026 ASCRS Meeting
1M ago
6K
OKYO
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
PremiumCompany Announcements
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial
2M ago
6K
OKYO
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
PremiumCompany Announcements
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3
2M ago
6K
OKYO
Okyo Pharma director John Brancaccio acquires 5,000 shares
PremiumThe Fly
Okyo Pharma director John Brancaccio acquires 5,000 shares
2M ago
OKYO
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
PremiumCompany AnnouncementsOKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress
2M ago
6K
OKYO
Okyo Pharma CDO, director acquire shares
Premium
The Fly
Okyo Pharma CDO, director acquire shares
2M ago
OKYO
Okyo Pharma reports results from Phase 2a trial of urcosimod
Premium
The Fly
Okyo Pharma reports results from Phase 2a trial of urcosimod
2M ago
OKYO
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
PremiumCompany Announcements
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option
2M ago
6K
OKYO
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
PremiumCompany Announcements
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026
2M ago
6K
OKYO
Okyo Pharma initiated with an Overweight at Piper Sandler
PremiumThe Fly
Okyo Pharma initiated with an Overweight at Piper Sandler
3M ago
OKYO
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
PremiumCompany Announcements
OKYO Pharma Prices $20 Million Underwritten Share Offering to Fund Clinical Development
3M ago
6K
OKYO
OKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
PremiumCompany AnnouncementsOKYO Pharma Prices $20 Million Public Share Offering to Fund Eye Disease Pipeline
3M ago
6K
OKYO
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
Premium
The Fly
Okyo Pharma $20M Spot Secondary; price range $1.80-$1.90
3M ago
OKYO
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
Premium
Company Announcements
OKYO Pharma Launches Public Offering to Fund Next Phase of Corneal Pain Drug Development
3M ago
6K
OKYO
Okyo Pharma announces ordinary shares offering, no amount given
PremiumThe Fly
Okyo Pharma announces ordinary shares offering, no amount given
3M ago
OKYO
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
PremiumCompany Announcements
OKYO Pharma Switches ATM Equity Facility to Leerink Partners to Support Urcosimod Push
3M ago
6K
OKYO
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
PremiumCompany Announcements
OKYO Pharma Launches $50 Million At-the-Market Share Offering With Leerink Partners
3M ago
6K
OKYO
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
PremiumCompany Announcements
OKYO Pharma Hires Oxervate Veteran Flavio Mantelli as Chief Medical Officer to Drive Urcosimod Program
3M ago
6K
OKYO
Okyo Pharma appoints Mantelli as Chief Medical Officer
PremiumThe FlyOkyo Pharma appoints Mantelli as Chief Medical Officer
3M ago
OKYO
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
Premium
Company Announcements
OKYO Pharma Advances Urcosimod With Positive Interim Results and FDA Alignment on Phase 2b/3 NCP Trial
3M ago
6K
OKYO
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
Premium
Company Announcements
OKYO Pharma’s Urcosimod Phase 2 Data Accepted for Presentation at 2026 ASCRS Meeting
3M ago
6K
OKYO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >